GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of 18 months in and hazard ratio is still the thing I get wrong — 47 comments in the full submission. View in context.
3.7k
c/trialwatch·submitted 1 year ago by u/ewan_tulloch

18 months in and hazard ratio is still the thing I get wrong

Readoutbranch of 5 comments

Genuinely asking, not being difficult. Everyone in c/bloodwork repeats that SELECT is important. I believe it, but I have never seen anyone show why, and when I search I get 17 threads of people agreeing with each other. Is there a paper? Is there a measurement? Or is this one of those things that is true because it…

Read the full submission and all 47 comments →

This branch

5 comments, started 1 year ago
u/joaquin_trevino102 points·1 year ago

Phase 2 or phase 3?

replysharereportpermalink
u/rulebook_rachaelmod · c/meta84 points·1 year ago

This is correct. Discontinuation arms show the regain reality.

replysharereportpermalink
u/emil_agyeman67 points·1 year ago·edited

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/draw_up_dizzy24 points·1 year ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/formulary_fighterappeals68 points·1 year ago·edited

Is that absolute or relative risk reduction?

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.